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Background: Improving the HBe seroconversion rate of patients without HBeAg loss after long-term lamivudine
therapy has become an urgent clinical problem that we have to face. Unfortunately, there is no consensus on the
mananement of these patients. The aim of this study was to evaluate the efficacy of pegylated interferon (PEG-IFN)
α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy.
Methods: Fifty patients with chronic hepatitis B without the loss of HBeAg after ≥96 weeks of lamivudine
treatment were enrolled to withdraw from treatment to induce a biochemical breakthrough. Patients who achieved
a biochemical breakthrough within 24 weeks received 48-weeks of PEG-IFN α2a therapy, and were then assessed
during a subsequent 24-week follow-up period.
Results: Forty-three (86.0%) patients achieved a biochemical breakthrough within 24 weeks of lamivudine
withdrawal. The rates of combined response (both undetectable HBV DNA and HBeAg loss) and HBsAg loss were
alone 51.2% and 20.9%, respectively after 48 weeks of PEG-IFN α2a therapy, and 44.2% and 18.6%, respectively, at
24 weeks after treatment cessation. The end-of-treatment combined response rate was 65.4% among patients with
a baseline HBsAg <20,000 IU/mL, which was significantly higher than 29.4% of patients with HBsAg ≥20,000 IU/mL
(P=0.031). For patients with HBsAg levels <1,500 IU/mL at 12 and 24 weeks therapy, the end-of-treatment
combined response rate was 68.2% and 69.0%, which were both significantly higher than patients with HBsAg
≥1,500 IU/mL (33.3% and 14.3%; P=0.048 and 0.001). The end-of-treatment combined response rate was
significantly higher among patients with HBV DNA<105 copies/mL (76.2%) compared to patients with HBV DNA
≥105 copies/mL (27.3%) after 24 weeks of therapy (P=0.004).
Conclusion: Retreatment with PEG-IFN α2a was effective and safe for patients without HBeAg loss after the
withdrawal of long-term lamivudine therapy. HBsAg levels at the baseline, 12 and 24 weeks of therapy, and HBV
DNA levels at 24 weeks of therapy, can predict the effect of PEG-IFN α2a after 48 weeks of therapy.
Keywords: Chronic hepatitis B, Pegylated interferon α2a, Lamivudine, Biochemical breakthroughBackground
Chronic infection with hepatitis B virus (HBV) is a
major global health problem, which affects more than
400 million people worldwide [1,2]. Approximately 15–
40% of infected patients develop cirrhosis, liver failure
or hepatocellular carcinoma (HCC). Appropriate anti-
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reproduction in any medium, provided the orpreventing advanced liver disease and reducing the num-
ber of HBV-related deaths.
The current treatment options for chronic HBV
infection consist of interferon-α (IFN-α) and nucleos(t)
ide analogues (NUCs), such as lamivudine, adefovir,
entecavir and telbivudine. Since lamivudine was initially
approved for the treatment of chronic HBV infection in
China, several million affected patients have received
long-term antiviral treatment with NUCs to prevent dis-
ease progression. Most patients hope that the period of
antiviral treatment is temporary. In HBeAg- positiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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end-point as it is associated with an improved prognosis
[1]. However, it is very difficult for most HBeAg positive
patients to meet the criteria for the cessation of
lamivudine treatment. In these patients, the rate of HBe
seroconversion with lamivudine treatment has been
reported to be 16-17% at 48 weeks, 17-29% at 96 weeks,
23-40% at 144 weeks, and 28-47% at 192 weeks [1-4].
Unfortunately, extended treatment with lamivudine is
associated with the development of drug resistance. The
cumulative incidence of HBV resistance to lamivudine is
24% at 1 year, 38% at 2 years, 49% at 3 years, 67% at 4 -
years, and 70% at 5 years. Therefore, it is very important
to institute new treatment strategies to improve the rate
of HBeAg loss or HBe seroconversion for patients with-
out HBeAg loss after long-term lamivudine treatment.
However, there are no definitive guidelines regarding
whether lamivudine therapy should be continued or a
new treatment should be commenced and the optimal
stopping point for receiving lamivudine treatment has
yet to be determined.
IFN-α exerts an antiviral effect by degrading viral
mRNA and proteins, and upregulates the immunological
response to HBV by enhancing human leukocyte antigen
class I expression on hepatocytes, its use has been
confirmed as effective in the treatment of chronic HBV
infection [1,5-8]. The use of pegylated interferon (PEG-
IFN) α has certain advantages over NUCs, which include
the absence of resistance, higher rates of HBeAg loss
and seroconversion, and higher rates of both sustained
off-treatment virological responses and HBsAg loss [1].
For HBeAg-positive patients with PEG-IFNα, higher
rates of HBeAg loss or seroconversion are associated
with higher pre-treatment serum alanine aminotransfer-
ase (ALT) levels. Additionally, post-treatment ALT flares
with viral proliferation often occur following the with-
drawal of lamivudine. Thus, a new retreatment strategy
that involves switching from lamivudine during a
withdrawal-induced ALT flare to PEG-IFN α2a therapy
is a reasonable protocol for patients without HBeAg loss
after long-term lamivudine treatment. However, neither
the efficacy nor safety of this new treatment strategy has
been fully demonstrated. The aim of our study was to
evaluate the use of PEG-IFN α2a therapy for the
retreatment of patients with chronic HBV infection after
a lamivudine withdrawal-induced biochemical break-
through. These patients were without HBeAg loss after
more than 96 weeks lamivudine treatment.
Methods
Selections of patients and study design
Inclusion criteria included: i) age 18–60 years; ii) con-
tinuous lamivudine treatment >96 weeks; iii) serum
HBV DNA levels <103 copies/mL;iv) positive for HBsAgand HBeAg, but negative for anti-HBs and anti-HBe;v)
normal liver function tests;vi) no history of liver failure
or cirrhosis,and the lack of cirrhosis confirmed by a
computed tomography scan; vii) neutrophil count ≥
1.5×109/L and platelet count ≥100×109/L. The exclusion
criteria included: i) superinfection with hepatitis A, C, D
or E, cytomegalovirus, HIV, or Epstein–Barr virus as
confirmed by enzyme-linked immunosorbent assay; ii)
other liver diseases such as alcoholic liver disease, drug-
induced hepatitis, Wilson disease and autoimmune
hepatitis; iii) severe medical or psychiatric illness; iv) a
history of diabetes, cardiac disease, hypertension, or
renal, pulmonary disease or thyroid disease; v) pregnant
or breastfeeding women; vi) an unwillingness or inability
to provide informed consent or fulfill the the require-
ments of the study.
Fifty outpatients with chronic hepatitis B (35 male, 15
female; median age, 33 years; range, 20–52 years) were
recruited at the Southwest Hospital, Third Military Med-
ical University, China, between January 2006 and June
2010. They were asked to withdraw from lamivudine
and any other medications. Liver function tests were
performed every 4 weeks. When a biochemical break-
through was observed, patients underwent a serum HBV
DNA test and retreatment with either PEG-IFN α2a
(180 μg, once per week) or lamivudine, in accordance
with the study design shown in Figure 1. This study was
conducted in accordance with the guidelines of the Dec-
laration of Helsinki. The ethics committee of Southwest
Hospital approved the study protocol, and all patients
gave witnessed, written informed consent.Laboratory assays
Serum HBsAg and anti-HBs, HBeAg and anti-HBe were
tested using the ARCHITECT (Abbott Laboratories).
The range of HBsAg detection was 0.05 to 250 IU/mL.
Serum HBV DNA was tested using real-time PCR
(Amplicor HBV Monitor Test, Roche Diagnostics,
Mannheim, Germany; the range of HBV DNA detection
was 103 to 109 copies/mL). We performed HBV genotyp-
ing by direct PCR sequencing in a residual serum sample
taken from each patient at the baseline timepoint before
they started the PEG-IFN α2a treatment.Evaluation of therapeutic effects and safety
We defined virological response as HBV DNA <103
copies/mL, serological response as HBeAg loss, biochemical
response as normalization of ALT level, and a combined
response as HBV DNA < 103 copies/mL and HBeAg
loss. We assessed both end-of-treatment combined re-
sponses after 48 weeks of PEG-IFN α2a therapy and
sustained combined responses at 24 weeks after the end
of treatment. The primary end point was sustained
Figure 1 Study design. Liver function was tested 4-weekly within 24 weeks of lamivudine withdrawal and 12-weekly after 24 weeks of
lamivudine withdrawal. ALT: alanine aminotransferase; ULN: upper limit of normal; IFN: interferon; T-Bil: total bilirubin; LAM: lamivudine.
Figure 2 Percentage of patients with biochemical breakthrough
occurred at the different time after lamivudine withdrawal.
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treatment combined responses and HBsAg loss.
In order to evaluate the safety of this study, serum
levels of ALT and total bilirubin (T-Bil) were tested 4-
weekly during lamivudine withdrawal and the first 12-
weeks of PEG-IFN α2a therapy. Patients undergoing
PEG-IFN α2a therapy were then tested every 12 weeks
during a further 60-week period. Peripheral leukocytes
and platelets were tested at weeks 4, 8, 12, 24, 48 and 72
of therapy. Serum free thyroxin 3 and 4 (FT3 and FT4),
thyroid stimulating hormone (TSH) were tested at the
baseline, then 12 weekly until the end of treatment. The
abnormal laboratory tests results and symptomatic ad-
verse effects were recorded and closely monitored at
each follow-up visit. We assessed all adverse events for
the likelihood of causality by the study drug.
Statistical analysis
We performed all statistical tests with SPSS, version 10.0
(SPSS, Inc., Chicago, IL, USA). We expressed continuous
variables as the median±standard deviation. The levels
of serum HBV DNA and HBsAg were logarithmically
transformed for the analyses. A P-value less than 0.05
was considered statistically significant. All statistical tests
were two-sided.
Results
Biochemical breakthrough induced by lamivudine
withdrawal
Forty-three (86.0%) patients were observed to have a
biochemical breakthrough (ALT levels ≥2×ULN) within
24 weeks of lamivudine withdrawal, and to have a viro-
logical breakthrough (HBV DNA ≥105 copies/mL). They
received a treatment with PEG-IFN α2a (Figure 2). Another
seven patients received a retreatment with lamivudine; a
subsequent biochemical breakthrough was observed in
four patients (8.0%) after 36 weeks of the initial lamivudine
withdrawal, and in three patients (6.0%) after 48 weeks of
lamivudine withdrawal. The characteristics of the patients
in this study are shown in Table 1. With the exception
of the median ALT levels at the time of the observedbiochemical breakthrough observed, there were no sta-
tistically significant difference with regards to age, gender,
genotype B, HBV DNA levels, and the duration of prior
lamivudine therapy between patients who had a biochem-
ical breakthrough occurred within 24 weeks of lamivudine
withdrawal and those in which it occurred after 24 weeks.Therapeutic efficacy of PEG-IFN α2a
Among 43 patients treated with PEG-IFN α2a therapy,
the rates of combined response (both HBV DNA <103
copies/ml and HBeAg loss) and HBsAg loss were 51.2%
and 20.9%, respectively, at the end of 48 weeks therapy,
and 44.2% and 18.6%, respectively, 24 weeks after the
end of treatment. The rates of undetectable HBV DNA,
HBeAg seroconversion and loss, and HBsAg seroconver-
sion were shown in Figure 3. Among six patients who
only showed a virological response at the end of 48 weeks
therapy, three patients had a sustained virological re-
sponse by 24 weeks after the end of treatment, but no
patient showed HBeAg loss. Among the 15 patients
without a virological response or HBeAg loss at the end
of 48 weeks therapy, only one patient had HBeAg loss
Table 1 The characteristics of the studied patients at the
occurrence of biochemical breakthrough
Characteristics Weeks of biochemical breakthrough
≤24 (n=43) >24 (n=7) p value
Age, yrs 32.5±7.9 37.1±5.8 NS
Men, n(%) 30(69.8%) 6(85.7%) NS
Duration of previous LAM 126±43 134±37 NS
treatment (weeks) (104–312) (104–208)
ALT level, n(%)
2-3×ULN 21(48.8%) 1(14.3%) NS
≥3×ULN 22(51.2%) 6(85.7%)
ALT level,IU/L 190±126 318±172 0.024
HBV DNA ≥1×107 copies/mL,% 29(67.4%) 6(85.7%) NS
HBV DNA(log10 copies/mL) 7.3±0.8 7.7±0.9 NS
HBV genotype, n (%)
B 30(69.8%) 5(71.4%) NS
C 12(27.9%) 2(28.6%)
B and C 1( 2.3%) 0(0)
ALT: alanine aminotransferase; ULN: upper limit of normal; LAM: lamivudine;
Weeks of biochemical breakthrough: Interval from lamivudine withdrawal to
biochemical breakthrough; NS: no significant difference.
Zhang et al. Virology Journal 2013, 10:21 Page 4 of 9
http://www.virologyj.com/content/10/1/21and seroconversion 24 weeks after the end of treatment,
but his HBV DNA level was 3.108×103 copies/mL.
Among the 22 patients with a combined response at the
end of 48 weeks therapy, 19 (86.4%) patients had a
sustained combined response 24 weeks after the end of
treatment. A normalization of the ALT levels was ob-
served in 25 patients (58.1%) at the end of 48 weeks
treatment, and among 32 patients (74.4%) by 24 weeks
after the end of treatment.Figure 3 The efficacy of pegylated interferon α2a for patients with HAll seven patients who received a retreatment with
lamivudine had an undetectable HBV DNA at 48 weeks
and 72 weeks of treatment, but none showed HBeAg
loss, HBe seroconversion, or HBsAg loss during the 72 -
weeks of lamivudine treatment.
The combined response and baseline characteristics of
patients
The baseline characteristics of patients with or without
combined response at the end of 48 weeks PEG-IFN α2a
therapy are shown in Table 2. There was no statistically
significant difference in the median levels of serum
HBsAg between patients with or without a combined re-
sponse at the end of the 48-week treatment (P=0.070,
Table 2), but the rate of combined response was signifi-
cantly higher among patients with HBsAg <20,000 IU/
mL than in patients with HBsAg levels ≥20,000 IU/mL
(P=0.031, Figure 4A). The rate of combined response
was higher among patients with HBV DNA levels <107
copies/mL than in patients with HBV DNA levels ≥107
copies/mL, but this was not significantly different
(P=0.104, Figure 4B). The rate of combined response
was also higher among patients with ALT levels
≥3×ULN compared to patients with ALT levels
<3×ULN, but again this difference was not significant
(P=0.131, Figure 4C). However, the rate of combined re-
sponse was significantly higher among patients with
ALT levels ≥3×ULN or HBV DNA levels <107 copies/
mL than in patients with both ALT levels <3×ULN and
HBV DNA levels ≥107 copies/mL (P=0.045, Figure 4D).
There were no significantly differences with age, gender
and genotype B between patients that had a combined
response and those that did not (Table 2).BeAg positive chronic hepatitis B.
Table 2 Baseline characteristics of patients with
pegylated interferon α2a
Characteristics Combined responses at 48 weeks
Yes (n=22) No (n=21) p value
Age, yrs 32.7±8.7 32.2±7.1 NS
Men, n(%) 13(59.1%) 17(81.0%) NS
ALT level, n(%)
≥3×ULN 14(63.6%) 8(38.1%) NS
ALT level,IU/L 209±137 171±113 NS
HBV DNA ≥1×107 copies/mL,% 12(54.5%) 17(81.0%) NS
HBV DNA(log10 copies/mL) 7.1±0.7 7.5±1.0 NS
HBsAg ≥2×104 IU/ml,% 5(22.7%) 12(57.1%) 0.031
HBsAg(log10 IU/mL) 3.8±0.8 4.2±0.6 0.070
HBV genotype, n (%)
B 15(68.2%) 15(71.4%) NS
C 7(31.8%) 5(23.8%)
B and C 0(0) 1( 4.8%)
ALT: alanine aminotransferase; ULN: upper limit of normal; combined
responses at 48 weeks: both HBV DNA< 1000 copies/ml and HBeAg loss at the
end of 48 weeks treatment; NS: no significant difference.
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during treatment
The rate of combined response at the end of 48 weeks
treatment was 61.5% among 26 patients with HBV
DNA <105copies/mL and 35.3% among 17 patients with
HBV DNA ≥105copies/mLat 12 weeks of therapy, but
this was not a significant finding (P=0.092). For patients
with HBV DNA <105 at 24 weeks of therapy, the rate of
combined response at the end of 48 weeks of therapy
reached 76.2%, which was significantly higher than in pa-
tients (27.3%) with HBV DNA ≥105copies/mL, P=0.004,
shown in Figure 5A. The baseline mean serum HBV DNA
was 7.20 ± 0.94 and 7.08±0.91 LC/mL among patients
with HBV DNA <105copies/mL at 12 weeks and 24 weeks
of therapy, which were lower than among patients with
HBV DNA ≥105copies/mL (7.53 ± 0.76 and 7.56±0.79 LC/
mL) at 12 weeks and 24 weeks of therapy; these were not
significant differences at either time point (P=0.232,
0.072). For patients with HBsAg <1,500 IU/mL at 12 weeks
and 24 weeks of therapy, the rates of combined response
at the end of 48 weeks were 68.2% and 69.0%, which were
significantly higher than in patients with HBsAg ≥1,500 IU/
mL (33.3% and 14.3%; P=0.048, 0.001; Figure 5B). The
baseline mean serum HBsAg was 3.63 ± 0.82 and 3.80 ±
0.79 log10 IU/mL in patients with HBsAg <1,500 IU/mL at
12 weeks and 24 weeks of therapy, which was significantly
lower than among patients with HBsAg ≥1,500 IU/mL
(4.43 ± 0.43 and 4.48 ± 0.44 Log10 IU/mL; P=0.0003, 0.004).
The rates of HBsAg loss at the end of 48 weeks treat-
ment were 31.0% (9/29), 38.9% (7/18) and 63.6% (7/11)
among patients with HBsAg < 1500, 100,10 IU/mL, butonly reached 0 (0/14), 8.0% (2/25) and 6.3% (2/32)
among patients with HBsAg ≥1500, 100,10 IU/mL at 24 -
weeks of therapy, having statistically significant differ-
ence (P=0.020, 0.038, 0.0003).
The rate of sustained combined response was significantly
higher among patients with HBV DNA <103 copies/mL
(67.9%, 19/28) or HBsAg <1500 IU/mL (59.4%, 19/32) com-
pared to that of patients with HBV DNA ≥103 copies/mL
(0, 0/15) or HBsAg ≥1500 IU/mL (0, 0/11) at the end of
48 weeks treatment, P<0.01.
Safety
From the withdrawal of lamivudine to the initiation of
PEG-IFN α2a treatment, none of 50 patients had any
evidence of hepatic decompensation or a severe acute
exacerbation of chronic HBV infection characterized by
ALT levels being >10×ULN or total bilirubin levels being
>51 μmol/L. During 48 weeks treatment with PEG-IFN
α2a, four (9.3%) patients developed a severe ALT flare-
up (ALT levels >10×ULN), of which two patients devel-
oped it at 4 weeks of treatment (749 IU/L and 535 IU/L,
respectively), one patient developed it at 8 weeks of
treatment (552 IU/L), and another patient at 12 weeks of
treatment (616 IU/L). At 24 weeks after the end of treat-
ment, two (4.7%) patients developed a severe ALT flare-
up (487 and 2042 IU/L). However, during 48 weeks
treatment with PEG-IFN α2a and 24-week follow up
period, T-Bil levels did not exceed 51 μmol/L among 43
patients. Other adverse symptoms and events related to
the use of PEG-IFN α2a included upper respiratory tract
symptoms (55.8%, 24/43), fever (69.8%, 30/43), alopecia
(32.6%, 14/43), abdominal discomfort (34.9%, 15/43),
malaise (69.8%, 30/43), headache (65.1%, 28/43), myalgia
(53.5%, 23/43), arthralgia (27.9%, 12/43), reduced appe-
tite (25.6%, 11/43), local erythematous reactions (9.3%,
4/43), weight loss (14.0%, 6/43), a decreased neutrophil
count (46.5%, 20/43) and a decreased platelet count
(51.2%, 22/43). No patient required a dosage adjustment
for PEG-IFN α2a, and no patient developed thyrotoxi-
cosis or hypothyroidism.
Discussion
Improving the HBe seroconversion rate of patients with-
out HBeAg loss after long-term lamivudine therapy has
become an urgent clinical problem that we have to face.
Unfortunately, there is no consensus on the manage-
ment of these patients. In this study, we administered a
new retreatment strategy by switching patients without
HBeAg loss after long-term lamivudine therapy with a
withdrawal-induced ALT flare to PEG-IFN α2a therapy.
The rationale of this new retreatment strategy was that
lamivudine withdrawal usually induces a biochemical
breakthrough and a host antiviral immune response, and
the biochemical breakthrough characterized by high
Figure 4 The association of the combined response rate at the end of 48 weeks pegylated interferon α2a treatment with serum levels
of ALT, HBV DNA and HBsAg at the baseline. ALT: alanine aminotransferase; ULN: upper limit of normal; LC/mL: Log10 copies/ml.
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IFN-α [1,9-13]. Our results also showed that lamivudine
withdrawal could induce biochemical breakthroughs,
and 86% patients relapsed within 24 weeks after the dis-
continuation of the initial lamivudine therapy. These
findings were similar to those reported by Shin JW, et al.
[11], and indicated that lamivudine withdrawal provided
a new opportunity for treatment with IFN-α in patients
without HBeAg loss.
Although patients who relapse after lamivudine with-
drawal can be treated with any available effective thera-
peutic agent, but treatment with NUCs has an indefinite
duration and causes low rates of HBeAg seroconversion
or loss, and furthermore, HBeAg seroconversion induced
by lamivudine retreatment is not permanent [1,10,11].
Therefore, retreatment with lamivudine or other NUCs
is not a good option for patients who relapse after
lamivudine withdrawal. However, retreatment with
standard IFNα was reported to have a similar efficacy tothe first IFN-α treatment in HBeAg-positive chronic
hepatitis B, and the efficacy of PEG-IFN α2a is better
than standard IFNα in treating HBeAg-positive chronic
hepatitis B [14]. Consequently, PEG-IFN α2a should be
considered as the first choice for patients who relapse
after lamivudine withdrawal. Wang Z et al. reported that
the rates of HBeAg loss and seroconversion were 18.9%
and 13.2% after 1 year of retreatment with a combin-
ation of lamivudine plus adefovir (36.0% and 28%) or
lamivudine alone (3.6% and 0%) for patients who re-
lapsed after lamivudine withdrawal [15]. However, our
results showed that the rates of combined response,
HBeAg loss and seroconversion reached 51.2%, 51.2%
and 30.2%, respectively, at the end of 48 weeks therapy
with PEG-IFN α2a in patients who relapsed after
lamivudine withdrawal, and none achieved HBeAg sero-
conversion and loss among a further seven patients
whoreceived retreatment with 72 weeks lamivudine.
These finding indicated that the effect of PEG-IFN α2a
Figure 5 The predictive values of HBV DNA and HBsAg levels during treatment for the combined response (HBeAg loss and
undetectable HBV DNA) at the end of 48 weeks treatment. LC/ml: Log10 copies/ml.
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relapsed after lamivudine withdrawal. More importantly,
HBeAg loss and seroconversion induced by lamivudine
treatment was not permanent, as 40%-60.7% patients
who had achieved HBeAg seroconversion or loss with
lamivudine relapsed after lamivudine withdrawal [11,16].
Our current results showed that the rates of combined
response, HBeAg loss and seroconversion were 44.2%,
48.8% and 34.9% at 24 weeks after the end of 48 weeks
PEG-IFN α2a treatment, and 86.4% patients who had a
combined response at the end of 48 weeks therapy had a
sustained combined response at 24 weeks after the end
of treatment. This indicated that the HBeAg loss and
seroconversion induced by PEG-IFN α2a treatment was
more durable than that induced by lamivudine for pa-
tients who relapsed after lamivudine withdrawal. Other-
wise, the rate of HBsAg loss reached 20.9% at the end of
48 weeks therapy with PEG-IFN α2a, and 18.6% at 24 -
weeks after the end of treatment in this study, which
was higher than the 0-3% reported with NUCs treatment
[1,11,15]. Therefore, our results preliminarily confirmed
that the retreatment strategy of switching from a
lamivudine withdrawal-induced ALT flare to PEG-IFN
α2a therapy provided a new opportunity to obtain a
sustained combined response off-treatment and a chance
of HBsAg loss in patients who had not achieved this
after long-term lamivudine treatment.
Recent studies indicated that HBsAg levels at the base-
line and during treatment can predict the effect of PEG-
IFN α in the treatment of chronic hepatitis B [16,17].
Our results also showed that the rate of combined re-
sponse at the end of 48 weeks therapy with PEG-IFNα2a was significantly higher among patients with base-
line levels of HBsAg <20,000 IU/mL than patients with
baseline levels of HBsAg ≥20,000 IU/mL, and was sig-
nificantly higher among patients with HBsAg <1,500 IU/
mL at 12 weeks and 24 weeks of therapy than patients
with HBsAg ≥1,500 IU/mL. The lower HBsAg levels
after 24 weeks of therapy, the higher rate of HBsAg loss
at the end of 48 weeks of therapy. These results further
confirmed that HBsAg levels at the baseline and during
treatment could predict the rate of a combined response
at the end of 48 weeks therapy. Furthermore, HBsAg
levels after 24 weeks of therapy may be helpful in
predicting HBsAg loss at the end of 48 weeks. Low viral
load and high serum ALT levels at the baseline have
been reported to be associated with a better response to
IFNαin other studies [1,6,7]. However, a statistically sig-
nificant difference was not observed in the rate of com-
bined response at the end of 48 weeks therapy with
PEG-IFN α2a between patients with baseline HBV DNA
≥107 copies/mL and baseline HBV DNA <107 copies/
mL. No significant difference was also found between
patients with baseline ALT ≥3×ULN and those with base-
line ALT <3×ULN in this study, which indicated that
baseline ALT level alone or HBV DNA level alone was
not a good indicators for predicting the effect of PEG-
IFN α2a therapy. Possible reasons for these results in-
cluded the fact that the sample size in this study was too
small to achieve a statistically significant difference, and
that the interaction of both ALT and HBV DNA affected
the response to treatment. Our results showed that the
rate of combined response was significantly higher
among patients with baseline ALT ≥3×ULN or HBV
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ALT <3×ULN and HBV DNA ≥107 copies/mL, which in-
dicated that combined baseline ALT and HBV DNA
levels may predict the effect of PEG-IFN α2a therapy,
and was better than ALT or HBV DNA levels alone. Our
results also showed that the rate of combined response
at the end of 48 weeks of therapy was significantly
higher among patients with HBV DNA <105 at 24 weeks
of therapy than those with levels ≥105copies/mL, indicated
that the HBV DNA level at 24 weeks of treatment might
be able to predict the response rate at the end of 48 weeks
of PEG-IFN α2a therapy, this had been described in other
studies [1,13]. Our results did not showed any significant
differences with regards to age, gender and genotype B
among patients with or without a combined response.
However, younger female patients with genotype B have
been shown to be more likely to have a good response to
interferon by other studies [1].
In this study, we also found that the rate of a sustained
combined response at 24 weeks after the end of treat-
ment was closely associated with HBeAg status, HBV
DNA levels and HBsAg levels at the end of 48 weeks
therapy. Therefore, we suggested that extended treat-
ment with PEG-IFN α2a may be helpful for patients who
only achieved virological response or combined response
but having high HBsAg levels at the end of 48 weeks
therapy, in order to achieve a better sustained combined
response. Long-term maintained therapy with NUCs
should be considered for patients without virological re-
sponse or HBeAg loss at the end of 48 weeks therapy.
Hepatic decompensation and severe acute exacerba-
tion of chronic hepatitis B induced by lamivudine with-
drawal are major clinical concerns. In this study, none of
50 patients had a severe acute exacerbation of chronic
hepatitis B during the 48 weeks follow-up after lamiv-
udine withdrawal, which indicated that the withdrawal
of lamivudine was safe for these patients without HBeAg
loss and underlying liver cirrhosis, if liver function tests
are monitored monthly for 24 weeks after lamivudine
withdrawal. Our results also indicated that lamivudine
withdrawal-induced hepatic decompensation and severe
acute exacerbation were uncommon events and could
be controlled for patients without underlying liver cir-
rhosis, which was in accordance with other previous re-
ports [9]. This study showed that interferon-α can be
given safely and effectively in patients with ALT levels
that were 2–10 times ULN and serum total bilirubin
≤51 μmol/L. For patients with ALT levels > 10 × ULN
or serum total bilirubin >51 μmol/L, lamivudine or other
NUCs was considered to be given [9]. For patients with
a severe acute exacerbation, combination therapy with
NUCs and corticosteroids have been confirmed to be ef-
fective in preventing the disease progression into hepatic
decompensation [18,19]. In this study, the incidencesof adverse events associated with PEG-IFN α2a treat-
ment were similar to those reported in other studies [6].
In conclusion, a retreatment strategy of switching to
PEG-IFN α2a therapy in patients with lamivudine
withdrawal-induced ALT flare was shown to be safe and
efficacious for patients without HBeAg loss and under-
lying liver cirrhosis after long-term lamivudine treat-
ment. A sustained combined off-treatment response and
HBsAg loss were achieved. HBsAg levels at the baseline,
12 and 24 weeks of therapy, and HBV DNA levels at 24 -
weeks of therapy were critical factors for predicting the
effect of 48 weeks therapy with PEG-IFN α2a. However,
our conclusions remain conservative because of the
small sample size and nonrandomized controlled study.
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